BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30065261)

  • 1. hTERT promoter mutations in chondrosarcomas associate with progression and disease-related mortality.
    Lin Y; Seger N; Chen Y; Hesla AC; Wejde J; Ghaderi M; Tsagkozis P; Larsson O; Haglund F
    Mod Pathol; 2018 Dec; 31(12):1834-1841. PubMed ID: 30065261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Profiling Identifies Association of
    Zhu GG; Nafa K; Agaram N; Zehir A; Benayed R; Sadowska J; Borsu L; Kelly C; Tap WD; Fabbri N; Athanasian E; Boland PJ; Healey JH; Berger MF; Ladanyi M; Hameed M
    Clin Cancer Res; 2020 Jan; 26(2):419-427. PubMed ID: 31615936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TERT promoter mutation is an objective clinical marker for disease progression in chondrosarcoma.
    Zhang Y; Chen Y; Yang C; Seger N; Hesla AC; Tsagkozis P; Larsson O; Lin Y; Haglund F
    Mod Pathol; 2021 Nov; 34(11):2020-2027. PubMed ID: 34108637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomerase promoter mutations and copy number alterations in solitary fibrous tumours.
    Lin Y; Seger N; Tsagkozis P; Hesla AC; Ghaderi M; Chen Y; Ehnman M; Warsito D; Wejde J; Larsson O; Haglund F
    J Clin Pathol; 2018 Sep; 71(9):832-839. PubMed ID: 29703757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Next-Generation Sequencing Identifies Molecular and Genetic Events in Dedifferentiated Chondrosarcoma.
    Lucas CG; Grenert JP; Horvai A
    Arch Pathol Lab Med; 2021 Aug; 145(8):1009-1017. PubMed ID: 33147331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct IDH1/2-associated Methylation Profile and Enrichment of
    Dermawan JKT; Nafa K; Mohanty A; Xu Y; Rijo I; Casanova J; Villafania L; Benhamida J; Kelly CM; Tap WD; Boland PJ; Fabbri N; Healey JH; Ladanyi M; Lu C; Hameed M
    Cancer Res Commun; 2023 Mar; 3(3):431-443. PubMed ID: 36926116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. H-ras oncogene mutation in dedifferentiated chondrosarcoma: polymerase chain reaction-restriction fragment length polymorphism analysis.
    Sakamoto A; Oda Y; Adachi T; Oshiro Y; Tamiya S; Tanaka K; Matsuda S; Iwamoto Y; Tsuneyoshi M
    Mod Pathol; 2001 Apr; 14(4):343-9. PubMed ID: 11301351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of human telomerase reverse transcriptase promoter region mutations C228T and C250T for overall survival in spinal chordomas.
    Bettegowda C; Yip S; Jiang B; Wang WL; Clarke MJ; Lazary A; Gambarotti M; Zhang M; Sciubba DM; Wolinsky JP; Goodwin CR; McCarthy E; Germscheid NM; Sahgal A; Gokaslan ZL; Boriani S; Varga PP; Fisher CG; Rhines LD
    Neuro Oncol; 2019 Aug; 21(8):1005-1015. PubMed ID: 30976795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features.
    Makise N; Sekimizu M; Konishi E; Motoi T; Kubo T; Ikoma H; Watanabe SI; Okuma T; Hiraoka N; Fukayama M; Kawai A; Ichikawa H; Yoshida A
    Mod Pathol; 2019 Mar; 32(3):435-445. PubMed ID: 30291346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.
    Chen S; Fritchie K; Wei S; Ali N; Curless K; Shen T; Brini AT; Latif F; Sumathi V; Siegal GP; Cheng L
    Hum Pathol; 2017 Jul; 65():239-246. PubMed ID: 28552826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. hTERT promoter methylation in meningiomas and central nervous hemangiopericytomas.
    Fürtjes G; Köchling M; Peetz-Dienhart S; Wagner A; Heß K; Hasselblatt M; Senner V; Stummer W; Paulus W; Brokinkel B
    J Neurooncol; 2016 Oct; 130(1):79-87. PubMed ID: 27465278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HTERT promoter methylation and single nucleotide polymorphism (-245 T>C) affect renal cell carcinoma behavior in Serbian population.
    Trifunovic J; Basta Jovanovic G; Nikolic N; Carkic J; Marjanovic A; Brankovic M; Radojevic Skodric S; Prvanovic M; Jovanovic A; Dzamic Z; Milasin J
    J BUON; 2018; 23(6):1887-1892. PubMed ID: 30610818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Telomerase Reverse Transcriptase Gene Promoter Mutation in Serum of Patients with Hepatocellular Carcinoma.
    Ako S; Nouso K; Kinugasa H; Matsushita H; Terasawa H; Adachi T; Wada N; Takeuchi Y; Mandai M; Onishi H; Ikeda F; Shiraha H; Takaki A; Fujioka S; Mimura T; Okada H
    Oncology; 2020; 98(5):311-317. PubMed ID: 32135540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age.
    Lötsch D; Ghanim B; Laaber M; Wurm G; Weis S; Lenz S; Webersinke G; Pichler J; Berger W; Spiegl-Kreinecker S
    Neuro Oncol; 2013 Apr; 15(4):423-32. PubMed ID: 23393205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta-analysis.
    Vuong HG; Ngo TNM; Dunn IF
    Cancer Med; 2021 Jul; 10(13):4415-4423. PubMed ID: 34085407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skull base chordoma and chondrosarcoma: influence of clinical and demographic factors on prognosis: a SEER analysis.
    Bohman LE; Koch M; Bailey RL; Alonso-Basanta M; Lee JY
    World Neurosurg; 2014 Nov; 82(5):806-14. PubMed ID: 25009165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression.
    van Beerendonk HM; Rozeman LB; Taminiau AH; Sciot R; Bovée JV; Cleton-Jansen AM; Hogendoorn PC
    J Pathol; 2004 Mar; 202(3):359-66. PubMed ID: 14991902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations.
    Kerr DA; Lopez HU; Deshpande V; Hornicek FJ; Duan Z; Zhang Y; Rosenberg AE; Borger DR; Nielsen GP
    Am J Surg Pathol; 2013 Jun; 37(6):787-95. PubMed ID: 23598960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conventional chondrosarcoma of the rib cage and sternum: clinicopathological and molecular analysis of 27 patients treated at a single institution.
    Abdulfatah E; Rottmann D; Morag Y; Pantanowitz L; Udager AM; Hao W; Lucas DR
    Hum Pathol; 2023 Jun; 136():63-74. PubMed ID: 37019410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.